News

Deal Announcements

Revance Adds To Third Venture Capital Round

Tuesday, May 13, 2008 5:56:00 AM PDT | VentureDeal Staff
MOUNTAIN VIEW, CA -- Pharmaceutical company Revance Therapeutics, Inc. said that it has added $8 million to close its series C round of financing at $51.2 million.

Revance is developing a topical botulinum toxin (BoTox) to eliminate the need for needle injections for administering the aesthetic drug.

Participants in the round extension were Essex Woodlands Health Trust, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, LLC, Medicis Pharmaceutical Corp., Bio*One Capital and Pac-Link Bio Venture Investment Corporation.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1